[go: up one dir, main page]

MX2019008302A - Inhibidores biciclicos de histona desacetilasa. - Google Patents

Inhibidores biciclicos de histona desacetilasa.

Info

Publication number
MX2019008302A
MX2019008302A MX2019008302A MX2019008302A MX2019008302A MX 2019008302 A MX2019008302 A MX 2019008302A MX 2019008302 A MX2019008302 A MX 2019008302A MX 2019008302 A MX2019008302 A MX 2019008302A MX 2019008302 A MX2019008302 A MX 2019008302A
Authority
MX
Mexico
Prior art keywords
desacetilase
histone
bicycle
inhibitors
hdac2
Prior art date
Application number
MX2019008302A
Other languages
English (en)
Other versions
MX394242B (es
Inventor
A Lowe John Iii
Oliver Fuller Nathan
Original Assignee
Rodin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodin Therapeutics Inc filed Critical Rodin Therapeutics Inc
Publication of MX2019008302A publication Critical patent/MX2019008302A/es
Publication of MX394242B publication Critical patent/MX394242B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan, en la presente, compuestos y sales de estos aceptables desde el punto de vista farmaceutico, y composiciones farmaceuticas de estos, que son utiles en el tratamiento de afecciones asociadas con la inhibicion de HDAC (por ejemplo, HDAC2).
MX2019008302A 2017-01-11 2018-01-11 Inhibidores biciclicos de histona desacetilasa MX394242B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445022P 2017-01-11 2017-01-11
US201762555298P 2017-09-07 2017-09-07
PCT/US2018/013260 WO2018132531A1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase

Publications (2)

Publication Number Publication Date
MX2019008302A true MX2019008302A (es) 2019-12-02
MX394242B MX394242B (es) 2025-03-24

Family

ID=61074595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008302A MX394242B (es) 2017-01-11 2018-01-11 Inhibidores biciclicos de histona desacetilasa

Country Status (27)

Country Link
US (7) US9951069B1 (es)
EP (2) EP3570834B1 (es)
JP (1) JP6756925B2 (es)
KR (1) KR102526032B1 (es)
CN (1) CN110290789B (es)
AU (1) AU2018207402B2 (es)
BR (1) BR112019014235A2 (es)
CA (1) CA3049443A1 (es)
CY (1) CY1125287T1 (es)
DK (1) DK3570834T3 (es)
ES (2) ES2875562T3 (es)
HR (1) HRP20220223T1 (es)
HU (1) HUE057849T2 (es)
IL (1) IL267953B2 (es)
LT (1) LT3570834T (es)
MA (1) MA47305A (es)
MD (1) MD3570834T2 (es)
MX (1) MX394242B (es)
PL (1) PL3570834T3 (es)
PT (1) PT3570834T (es)
RS (1) RS62959B1 (es)
SG (1) SG11201906164RA (es)
SI (1) SI3570834T1 (es)
SM (1) SMT202200131T1 (es)
TW (1) TWI770104B (es)
WO (2) WO2018132531A1 (es)
ZA (1) ZA201904459B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) * 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
CA3143188A1 (en) * 2019-06-13 2020-12-17 Dana-Farber Cancer Institute, Inc. Hdac3 catalytic inhibitor development and uses thereof
US20220267323A1 (en) 2019-07-23 2022-08-25 Alkermes, Inc. Synthesis of bicyclic inhibitors of histone deacetylase
CN110734924B (zh) * 2019-10-25 2020-10-23 山东大学第二医院 一种抑郁症检测、治疗和预后靶点及应用
CN118715206A (zh) 2021-12-03 2024-09-27 探戈医药股份有限公司 新型hdac抑制剂及其治疗用途

Family Cites Families (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP3169413B2 (ja) 1992-01-31 2001-05-28 エーザイ株式会社 イミダゾール誘導体
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
NZ301265A (en) 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP2000507590A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
JPH1149676A (ja) 1997-07-31 1999-02-23 Geron Corp ピリジン系テロメラーゼ阻害剤
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
ATE336480T1 (de) 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HU230538B1 (hu) 2000-08-14 2016-11-28 Ortho Mcneil Pharmaceutical, Inc. Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
CZ2003635A3 (cs) 2000-09-06 2004-12-15 Ortho Mcneil Pharmaceutical, Inc. Substituovaný pyrazol a jeho použití
WO2002026708A1 (en) 2000-09-27 2002-04-04 Toray Industries, Inc. Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
NZ526336A (en) 2000-12-07 2004-11-26 Cv Therapeutics Inc Substituted 1, 3,5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
PL369598A1 (en) 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002305450A1 (en) 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
US20040248850A1 (en) 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
SI1867644T1 (sl) 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
TWI287567B (en) 2003-07-30 2007-10-01 Chi Mei Optoelectronics Corp Light-emitting element and iridium complex
EP1651638A1 (en) 2003-08-08 2006-05-03 Janssen Pharmaceutica N.V. Pyridyl piperazinyl ureas
CN101031539A (zh) 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
MXPA06010520A (es) 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
JP4777974B2 (ja) 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体作用物質、製剤および治療的使用
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
DE602005026962D1 (de) 2004-10-19 2011-04-28 Compass Pharmaceuticals Llc Arylcarboxamide und ihre verwendung als antitumormittel
JP2008519814A (ja) 2004-11-12 2008-06-12 ガラパゴス・ナムローゼ・フェンノートシャップ プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
US8946444B2 (en) 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
MX2007008474A (es) 2005-01-14 2008-02-19 Chemocentryx Inc Sulfonamidas de heteroarilo y ccr2.
EP1683796A1 (en) 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
JP2008545624A (ja) 2005-05-13 2008-12-18 チバ ホールディング インコーポレーテッド 金属錯体を含むケラチン繊維を着色するための方法
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
BRPI0613535A2 (pt) 2005-06-02 2011-01-18 Bayer Cropscience Ag derivados de heteroarila substituìda por fenilalquila
JP2008543754A (ja) 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
WO2006137772A1 (en) 2005-06-20 2006-12-28 Astrazeneca Ab New physical form of n,n´- disubstituted oxabispidines
ATE455103T1 (de) 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
JP2009514858A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
DK2774925T3 (en) 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
WO2007071598A1 (en) 2005-12-23 2007-06-28 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
AU2007208494A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Fluorinated arylamide derivatives
US20090062297A1 (en) 2006-01-12 2009-03-05 Heidebrecht Richard W Hydroxyalkylarylamide Derivatives
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
JP2007283748A (ja) 2006-03-23 2007-11-01 Fujifilm Corp 光記録媒体および可視情報記録方法
SI2656841T1 (sl) 2006-03-27 2016-11-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji
ES2452820T3 (es) 2006-04-07 2014-04-02 Methylgene, Inc. Derivados de benzamida como inhibidores de histona desacetilasa
WO2007125984A1 (ja) 2006-04-28 2007-11-08 Nihon Nohyaku Co., Ltd. イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
EP2016068A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Pyrazole derivatives and their use as pi3k inhibitors
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
DE602007006010D1 (de) 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2007143557A2 (en) 2006-06-02 2007-12-13 Brandeis University Compounds and methods for treating mammalian gastrointestinal parasitic infections
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
WO2008010985A2 (en) 2006-07-20 2008-01-24 Merck & Co., Inc. Phosphorus derivatives as histone deacetylase inhibitors
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008011611A2 (en) 2006-07-21 2008-01-24 Irm Llc Compounds and compositions as itpkb inhibitors
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2008013963A2 (en) 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008024970A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
CN101796056A (zh) 2006-09-18 2010-08-04 沃泰克斯药物股份有限公司 c-MET的杂环抑制剂及其用途
ATE493984T1 (de) 2006-10-18 2011-01-15 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
JPWO2008053913A1 (ja) 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
US20080145816A1 (en) 2006-12-15 2008-06-19 Hershey Adrienne A Yankauer suction device
BRPI0720588B8 (pt) 2006-12-21 2021-05-25 Nerviano Medical Sciences Srl derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
JP2008179067A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP2008179068A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP5539734B2 (ja) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チオピリミジンベースの化合物およびその使用
CN101679347B (zh) 2007-03-20 2014-10-22 柯瑞斯公司 作为hsp90抑制剂的稠和的氨基吡啶
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2008129280A1 (en) 2007-04-20 2008-10-30 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2008139152A1 (en) 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
MX2009013169A (es) 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
WO2008151211A1 (en) 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
US8354383B2 (en) 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
CA2700058A1 (en) 2007-09-19 2009-03-26 4Sc Ag Novel tetrahydrofusedpyridines
JP5469604B2 (ja) * 2007-09-19 2014-04-16 ４エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
CA2702946A1 (en) 2007-10-16 2009-04-23 Northeastern University Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity
US20090156825A1 (en) 2007-11-26 2009-06-18 Heidebrecht Jr Richard W Fluorescent compounds that bind to histone deacetylase
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
RU2010151352A (ru) 2008-06-20 2012-07-27 Метаболекс, Инк. (Us) Арильные агонисты grp119 и их применения
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
WO2010006191A1 (en) 2008-07-11 2010-01-14 Irm Llc 4-phenoxymethylpiperidines as modulators of gpr119 activity
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
UY32146A (es) 2008-09-29 2010-04-30 Boehringer Ingelheim Int Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
WO2010108921A1 (en) 2009-03-27 2010-09-30 Nerviano Medical Sciences S.R.L. N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
WO2010112520A1 (en) 2009-04-01 2010-10-07 Novartis Ag Spiro derivatives for the modulation of stearoyl-coa desaturase
US8334315B2 (en) 2009-05-07 2012-12-18 Gruenenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2521724B1 (en) 2009-12-11 2016-11-23 Nono Inc. Agents and methods for treating ischemic and other diseases
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011119869A1 (en) 2010-03-24 2011-09-29 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
EP2557078B1 (en) 2010-04-06 2016-03-23 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US20140018538A1 (en) 2010-08-20 2014-01-16 President And Fellows Of Harvard College High-valent palladium fluoride complexes and uses thereof
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
WO2012074050A1 (ja) 2010-12-01 2012-06-07 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板、液晶表示装置、及び化合物
JP5992435B2 (ja) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 循環からの生体分子の除去剤
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
EP2668162A1 (en) 2011-01-28 2013-12-04 Novartis AG Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
US20140057953A1 (en) 2011-03-03 2014-02-27 Rolf Hartmann Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
BR112013023914A2 (pt) 2011-03-18 2016-12-13 Lupin Ltd derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2012257417B2 (en) 2011-05-16 2017-09-14 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
KR20140049027A (ko) 2011-07-26 2014-04-24 그뤼넨탈 게엠베하 치환된 헤테로사이클릭 아자 유도체
BR112014001880A2 (pt) 2011-07-26 2017-02-21 Gruenenthal Gmbh derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
EP2742027A1 (en) 2011-08-12 2014-06-18 Basf Se N-thio-anthranilamide compounds and their use as pesticides
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
AR087971A1 (es) 2011-09-23 2014-04-30 Bayer Ip Gmbh Uso de derivados del acido 1-fenil-pirazol-3-carboxilico 4-sustituidos como principios activos contra estres abiotico de plantas
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6113828B2 (ja) 2012-04-04 2017-04-12 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
CN104245714B (zh) 2012-04-12 2017-09-26 港大科桥有限公司 供oled应用的铂(ii)络合物
US20150105433A1 (en) 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
JP6217629B2 (ja) 2012-05-31 2017-10-25 住友化学株式会社 縮合複素環化合物
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
MX2014015156A (es) 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
EP2861588A4 (en) 2012-06-15 2016-04-20 Univ California NEW THERAPEUTICS FOR BRAIN CANCER
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9682970B2 (en) 2012-06-29 2017-06-20 Biotium, Inc. Fluorescent compounds and uses thereof
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US9738623B2 (en) * 2012-08-06 2017-08-22 The General Hospital Corporation Curcumin analogs
EP2888256A4 (en) 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
MX2015004511A (es) 2012-10-11 2015-07-06 Grünenthal GmbH Tratamiento y/o profilaxis de enfermedades y/o trastornos provocados por tspo.
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
KR20150093685A (ko) 2012-11-09 2015-08-18 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 Hbv 어셈블리 이펙터의 대체 용도
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
EP4245744A3 (en) 2012-11-22 2024-05-01 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081301A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014089112A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
CN103864754B (zh) 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
US9890127B2 (en) 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2970219B1 (en) 2013-03-15 2019-02-27 Epizyme, Inc. Carm1 inhibitors and uses thereof
AU2014238443A1 (en) 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014146995A1 (en) 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104163791B (zh) 2013-05-20 2017-05-03 湖南化工研究院 N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用
CN104163792B (zh) 2013-05-20 2017-04-12 湖南化工研究院 N‑吡啶酰胺类化合物及其制备方法与应用
US20160194299A1 (en) 2013-05-24 2016-07-07 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
US9957289B2 (en) 2013-05-30 2018-05-01 Washington University Compounds and methods for treating bacterial infections
KR102349659B1 (ko) 2013-06-10 2022-01-11 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 개질된 방출 스펙트럼을 갖는 인광성 네자리 금속 착물
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
SG11201601066VA (en) 2013-09-06 2016-03-30 Inception 2 Inc Triazolone compounds and uses thereof
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
WO2015051458A1 (en) 2013-10-08 2015-04-16 Lu qing-bin Non-platimun-based anti-cancer compounds for use in targeted chemotherapy
PT3060550T (pt) 2013-10-21 2019-08-27 Merck Patent Gmbh Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos
WO2015077246A1 (en) 2013-11-19 2015-05-28 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
CN103601718A (zh) 2013-12-05 2014-02-26 江西天人生态股份有限公司 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
CN103804312B (zh) 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015142903A2 (en) 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
GB201405002D0 (en) 2014-03-20 2014-05-07 Isis Innovation Fluorination method
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US11691997B2 (en) 2014-04-09 2023-07-04 Lumiphore, Inc. Macrocycles
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016018795A1 (en) 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
US9969744B2 (en) 2014-08-04 2018-05-15 Fundación La Investigación Médica Aplicada Compounds for use in cognition improvement
WO2016028391A2 (en) 2014-08-18 2016-02-25 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016100711A1 (en) 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
CN106083823A (zh) 2015-04-30 2016-11-09 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
CA2983314C (en) 2015-04-30 2024-11-12 Memorial Sloan-Kettering Cancer Center Mitragynine analogues and their uses
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
WO2017027984A1 (en) 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
EP3362436B1 (en) 2015-09-14 2021-06-30 Universiteit Antwerpen Process for the catalytic directed cleavage of amide-containing compounds
WO2017075694A1 (en) 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
DK3269370T3 (da) 2016-02-23 2020-04-06 Taiho Pharmaceutical Co Ltd Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf
US11179710B2 (en) 2016-03-09 2021-11-23 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018098296A1 (en) 2016-11-23 2018-05-31 Regenacy Pharmaceuticals, Llc Piperazine derivatives as selective hdac1,2 inhibitors
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
CN106946890A (zh) 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
MX2021000468A (es) 2018-07-13 2021-06-23 Alkermes Inc Inhibidores de la histona desacetilasa.
AU2019301761A1 (en) 2018-07-13 2021-01-14 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase

Also Published As

Publication number Publication date
CA3049443A1 (en) 2018-07-19
US10793567B2 (en) 2020-10-06
US11225479B2 (en) 2022-01-18
JP6756925B2 (ja) 2020-09-16
IL267953B (en) 2022-10-01
TWI770104B (zh) 2022-07-11
IL267953A (en) 2019-09-26
SMT202200131T1 (it) 2022-05-12
US20200148678A1 (en) 2020-05-14
MD3570834T2 (ro) 2022-04-30
AU2018207402A1 (en) 2019-07-18
PL3570834T3 (pl) 2022-05-23
JP2020504156A (ja) 2020-02-06
DK3570834T3 (en) 2022-02-28
ES2909086T3 (es) 2022-05-05
US10696673B2 (en) 2020-06-30
US11987580B2 (en) 2024-05-21
CN110290789B (zh) 2022-10-18
KR102526032B1 (ko) 2023-04-25
US20190337953A1 (en) 2019-11-07
EP3570834A1 (en) 2019-11-27
EP3568135A1 (en) 2019-11-20
RS62959B1 (sr) 2022-03-31
PT3570834T (pt) 2022-03-01
IL267953B2 (en) 2023-02-01
US10519149B2 (en) 2019-12-31
US11286256B2 (en) 2022-03-29
MX394242B (es) 2025-03-24
US9951069B1 (en) 2018-04-24
EP3570834B1 (en) 2021-12-22
SG11201906164RA (en) 2019-08-27
US20210053964A1 (en) 2021-02-25
CY1125287T1 (el) 2023-06-09
US20210122748A1 (en) 2021-04-29
HRP20220223T1 (hr) 2022-04-29
HUE057849T2 (hu) 2022-06-28
TW201831183A (zh) 2018-09-01
AU2018207402B2 (en) 2023-09-28
BR112019014235A2 (pt) 2020-03-17
WO2018132531A1 (en) 2018-07-19
ZA201904459B (en) 2021-02-24
WO2018132533A1 (en) 2018-07-19
US20220340560A1 (en) 2022-10-27
SI3570834T1 (sl) 2022-05-31
LT3570834T (lt) 2022-03-10
US20180215759A1 (en) 2018-08-02
EP3568135B1 (en) 2021-04-07
CN110290789A (zh) 2019-09-27
ES2875562T3 (es) 2021-11-10
MA47305A (fr) 2019-11-27
KR20190104389A (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
CY1125193T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν μελοξικαμη
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
MX2020009115A (es) Inhibidores de cd73.
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
ECSP19051352A (es) Inhibidores selectivos de jak1
NI201900052A (es) Formulaciones farmacéuticas
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
SV2017005597A (es) Compuestos inhibidores de la señalizacion de la via de notch
CO2020007895A2 (es) Inhibidores de histona acetiltransferasa de la familia myst
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CY1125199T1 (el) Δικυκλικοι αναστολεις αποακετυλασης της ιστονης
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
CL2017000026A1 (es) Formas de dosificación farmacéutica
CL2016003271A1 (es) Métodos para tratar infecciones
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
EA201991542A1 (ru) Бициклические ингибиторы деацетилазы гистонов
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
CR20190240A (es) Formulaciones farmaceuticas
EA202090930A1 (ru) Соединения, пригодные для ингибирования cdk7
EA201991085A1 (ru) Фармацевтические составы